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3βHSD – 3-beta-hydroxysteroid dehydrogenase 
ANGPT (1/2) – angiopoietin (1/2) 
ANOVA – analysis of variance 
AP1 – activator protein 1 
cAMP – cyclic adenosine monophosphate 
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CD (4/8) – cluster of differentiation 4/8) 
cJUN – JUN proto-oncogene 
CL – corpus luteum 
dbcAMP – N6,2-dibutyryladenosine-3,5-cyclic 
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DEGs – differentially expressed genes 
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ERα/ESR1 – estrogen receptor alpha 
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ET (A/B) – endothelin receptor (A/B) 
FAS – Fas cell surface death receptor 
FASLG – Fas ligand 
FGF (1/2) – fibroblast growth factor (1/2) 
FSH – follicle stimulating hormone 
GATA (4/6) – GATA binding protein (4/6) 
GLUT1/SLC2A1 – glucose transporter 1/solute carrier 
family 2 member 1 
GnRH – gonadotropin-releasing hormone 
HSD17B7 – hydroxysteroid 17b dehydrogenase 7 
i.a. – inter alia, among other things 
i.e. – id est, that is 
ICAM1 – intercellular adhesion molecule 1 
IHC – immunohistochemistry 
IL (1β/6/8/10/12a) – interleukin (1 beta/6/8/10/12 
subunit alpha) 
IP3 – inositol 1,4,5-triphosphate 
KDM4A – lysine (K)-specific demethylase 4A 
LH – luteinizing hormone 
MHCII – major histocompatibility complex II 
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PGE2 – prostaglandin E2 
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PGI2 – prostaglandin I2 
PGR – nuclear progesterone receptor 
PPARγ – peroxisome proliferator activated receptor 
gamma 
PTGDR/DP – prostaglandin D receptor 
PTGDS – prostaglandin D synthase 
PTGER (1-4)/EP (1-4) – prostaglandin E receptor (1-4) 
PTGES – prostaglandin E synthase 
PTGFR/FP – prostaglandin F receptor 
PTGFS – prostaglandin F synthase 
PTGIR/IP – prostaglandin I receptor 
PTGIS – prostaglandin I synthase 
PTGS/COX (1/2) – prostaglandin synthase / 
cyclooxygenase (1/2) 
PTK2 – protein tyrosine kinase 2 
RNA-Seq – RNA sequencing 
RT-qPCR – semi quantitative real time (TaqMan) 
polymerase chain reaction 
SD – standard deviation 
SF1 – steroid factor 1 
STAR – steroidogenic acute regulatory protein 
STS – steroid sulfatase 
SULT1E1 – sulfotransferase family 1E member 1 
TXA2 – thromboxane A2 
TBXAS1 – thromboxane A synthase 1 
TBXAS2R/TP – thromboxane A2 receptor 
TGFβ – transforming growth factor β 
THBS (1) – thrombospondin (1) 
Tie (1/2) – tyrosine kinase with immunoglobulin-like 
and EGF-like domains (1/2) 
TNFR (1/2) – tumor necrosis factor receptor (1/2) 
TNFα – tumor necrosis factor alpha 
VEGF (A) – vascular endothelial growth factor (A) 
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Xg – geometric mean 















The reproductive cycle of the dog (Canis lupus familiaris) presents a plethora of unique features 
when compared with other mammals. The absence of steroidogenic activity in the placenta gives 
the corpus luteum (CL) a crucial role in the outcome of pregnancy. Furthermore, the lack of an 
active luteolytic principle in the form of extraluteal (i.e., uterine) or intraluteal prostaglandin (PG) 
F2α in non-pregnant bitches results in the presence a prolonged physiological pseudopregnancy. 
The latter is frequently longer than pregnancy itself, presenting circulatory progesterone (P4) levels 
similar to those of pregnant animals, and terminates with a slow and passive CL degeneration. 
Adding to these events the long obligatory sexual quiescence (anestrus), an extended reproductive 
cycle is observed in the dog, in which the CL plays a central role in its regulation. Thus, 
understanding of CL regulation and function is critical for the understanding of canine 
reproduction. 
The regulation of CL function in the dog is also peculiar. It can be subdivided into two regulatory 
stages: an early gonadotropin-independent period of CL formation and development, and the mature 
CL dependent on gonadotropins, predominantly prolactin (PRL), for its function. The early 
independence on hypophysial hormones suggests an intrinsic regulation of the CL through factors 
acting in an auto/paracrine way. Prostaglandins (PGs), primarily PGE2, are proposed to be among 
these factors. Prostaglandins are active lipid compounds that exhibit hormone-like effects in 
different systems. In the reproductive cycle, functional responsibilities between the luteotropic 
PGE2 and luteolytic PGF2α were demonstrated in several species. In the dog, the idea that PGE2 
could perform luteotropic roles derived from the observed increased availability of PTGS2/COX2 
and PGE2 synthase (PTGES) that led to increased levels of PGE2 within the CL during its early 
stages. In addition, the stimulatory role of PGE2 on steroidogenesis in primary canine luteal cells 
supports this idea. Furthermore, the in vivo effects of firocoxib (Previcox®, Merial), a COX2-
specific inhibitor, provided the final demonstration of the luteotropic effects of PGs in the dog. In 
this study, non-pregnant bitches treated for up to 30 days after ovulation with firocoxib exhibited 
lower luteal levels of PGE2, lower expression of several steroidogenic factors and, consequently, 
lower circulating levels of P4. Besides these direct effects of PGs, predominantly of PGE2 in 
steroidogenesis, further indirect effects were observed in vitro, where PGE2 regulated expression of 
the vasodilatory endothelin (ET) receptor B (ETB) and ET2, and of angiopoietin 1 and -2 
(ANGPT1, -2) which are involved in vascular stabilization. Further indirect effects of PGs appear to 




In this context, the goal of the present PhD work was to extend knowledge on the modulatory role 
of PGs in the CL. For this, samples from the previously described in vivo study were used. These 
samples were divided into control and treated groups (n=3-5 animals/group), collected on the day of 
ovulation (day 0) or at days 5, 10, 20 or 30 after ovulation. 
The previously described effects of PGE2 on vascular factors, and its regulatory effects on the 
activity of the immune system in several organs, prompted the hypothesis that PGs could be 
involved in the regulation of CL vascularization and immune response. In fact, based on the results 
obtained in this PhD thesis, PGs appear to exhibit both vaso- and immunomodulatory effects in the 
canine CL. After treatment, the expression of vascular factors belonging to the ANGPT-system, 
evaluated with semi-quantitative real time (TaqMan) qPCR, was decreased. In addition, the 
expression of endothelin 1 (ET1; typically linked to luteolysis), of pro-inflammatory interleukins 
(IL) -1β, -6 and -12, and of CD4, was increased (P>0.05) after treatment. Immunohistochemistry 
was used to validate these effects at the protein level. Interestingly, these Previcox-evoked changes 
related mostly to days 20 and 30.  
The effects observed in the first study upon withdrawal of PGs encouraged us to perform a deep 
RNA sequencing (RNA-Seq; Next Generation Sequencing, NGS). Treatment-dependent effects 
were assessed by comparing samples from treated and control dogs. Interestingly, these effects 
appeared to be stage-dependent, reflected in large differences in the number of differentially 
expressed genes (DEGs, P<0.01, FDR<0.1) per contrast, and absence of genes concomitantly 
affected in all studied time-points. Days 5 and 10 (representing the early gonadotropin-independent 
stage) were weakly affected by treatment, presenting respectively 74 and 2 DEGs. These low 
effects in the early developing CL suggest the presence of compensatory mechanisms to treatment. 
In contrast, higher numbers of DEGs (1741) were found on day 20 (representing the transition 
towards gonadotropin-dependency), mainly related to increased cellular growth/proliferation and 
immune function. The 552 DEGs found on day 30 (representing the mature PRL-dependent CL) 
were mainly related to decreased steroidogenic function and vascularization. This analysis 
suggested the presence of stage-dependent and multidirectional effects of COX2-inhibition in luteal 
function and the presence of strong compensatory effects in the early canine CL. In addition to 
treatment-induced effects, time-dependent changes in the expression of many factors were also 
analyzed. Several of these were described for the first time in the CL, being involved in luteal 
vascularization, immunity, sensitivity to steroids and transcriptional regulation of STAR. 
Cumulatively, this PhD work provides new information regarding the effects of PGs in the 
modulation of CL function and changes in mechanisms regulating maturation of the CL. The 






1.1 Prostaglandins  
1.1.1. Synthesis, signaling and main roles  
Prostaglandins (PGs) are arachidonic acid-derived eicosanoids (active lipid compounds) exhibiting 
hormone-like effects in the body. The family includes PGE2, PGF2α, PGI2, PGD2 and 
thromboxane A2 (TXA2). These lipid compounds are found in most tissues, acting in a plethora of 
mechanisms, including inflammation, vascular relaxation and/or constriction, platelet aggregation, 
sleep regulation, bronchoconstriction, allergic reactions and regulation of reproduction (Breyer, et 
al. 2001, Hata and Breyer 2004, Murdoch, et al. 1993, Weems, et al. 2006). Due to their short life 
period, PGs act mostly at a local level through their specific transmembrane receptors. Specific 
receptors were described for particular prostaglandins [(Fig.1) (Breyer, et al. 2001, Hata and Breyer 
2004)]. Additionally, splice variants could be observed in some cases, e.g., for PTGFR/FP, 
TBXA2R/TP, PTGER1/EP1 and PTGER3/EP3 (Breyer, et al. 2001). Regarding PGE2, four 
receptor subtypes were described: PTGER1/EP1, -2, -3 and -4 [(Fig.1) (Breyer, et al. 2001, Hata 
and Breyer 2004)]. Their activity varies based on structure, but also on their affinity to the ligand 
(PGE2) and the downstream pathways they activate. For example, while activation of PTGER1/EP1 
leads to inositol 1,4,5-triphosphate (IP3)-dependent increase in intracellular calcium ion 
concentration, PTGER2/EP2 and -4 signals are cAMP-mediated (Breyer, et al. 2001, Hata and 
Breyer 2004).  
The activity of prostaglandin-endoperoxide synthases/cyclooxygenases (PTGS1/COX1 or 
PTGS2/COX2) is indispensable in PGs biosynthesis (Smith 1992, Smith and Dewitt 1996). Of 
these, PTGS2/COX2 is an inducible enzyme that is expressed in response to different stimuli such 
as cytokines and growth factors (Hata and Breyer 2004, Smith and Dewitt 1996). These enzymes 
exhibit both dioxygenase and peroxidase activity, converting membrane-derived arachidonic acid 
(released by phospholipase A2), via PGG2 as an intermediate, into PGH2 [(Fig. 1) (Smith 1992, 
Smith and Dewitt 1996)]. In subsequent downstream synthesis steps, PGH2 functions as a single 
precursor for all active PGs [(Fig.1) (Smith 1992)]. Moreover, some enzymes can interconvert PGs, 
as in the case of PGE2-9-ketoreductase which utilizes PGE2 for PGF2α synthesis (Watson, et al. 
1979). Such a mechanism has been implicated as the main PGF2a synthesis route in the canine 
prepartum placenta (Gram, et al. 2014). Thus, the production of different PGs in specific tissues is 
determined by the expression of their synthases and/or converting enzymes (Breyer, et al. 2001, 
Smith 1992). Notably, the inhibition of PGs synthesis can be achieved by blocking the activity of 
COX1 and/or COX2 using different compounds that might present a higher affinity/specificity for 
one of these enzymes. In this way, e.g., acetylsalicylic acid inhibits COX1 activity, oxicams (e.g., 
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meloxicam and piroxicam) are preferential inhibitors of COX2 but also affect COX1 activity, 
coxibs (e.g., celecoxib, robenacoxib and firocoxib) are COX2-specific inhibitors while 
indomethacin is a nonselective inhibitor of both cyclooxygenases (FitzGerald and Patrono 2001, 
Smith and Dewitt 1996, Weems, et al. 2006).  
 
Figure 1. Prostaglandin synthesis pathway. Arachidonic acid is converted into PGG2 and then into PGH2 
by PTGS/COX1 and -2. PGH2 can then be converted into TXA2, PGD2, PGE2, PGI2 or PGF2α through 
their specific synthases which bind to PG-specific receptors (Adapted from Hata and Breyer 2004). 
 
1.1.2. Roles in female reproduction 
In female reproductive physiology, the effects of PGE2 and PGF2α are considered indispensable in 
several mechanisms. Both PGE2 and PGF2α have been found in follicular fluid and modulate 
oocyte maturation (Murdoch, et al. 1993, Weems, et al. 2006). For ovulation to occur, PGF2α 
locally induces collagenolysis in the Graafian follicle and the use of COX-blockers can affect or 
even prevent ovulation in species such as the rat, mouse, cattle, pig, horse, sheep or human 
(reviewed in Murdoch, et al. 1993). Also, horse embryos secrete PGE2 before implantation (Weber, 
et al. 1991), while in the dog and pig an increased expression of endometrial PTGES is observed in 
the presence of embryos (Kautz, et al. 2014, Wasielak, et al. 2009). In the murine uterus, PGE2 also 
exhibits immuno-modulatory effects that implicate its support in the feto-maternal immune 
tolerance (Mason, et al. 2013). Interestingly, PGE2 and PGF2α frequently exhibit opposing effects. 
For example, in the uterus, PGF2α induces smooth muscle contraction, either directly or by 
stimulating increased 17β-estradiol (E2) levels, while PGE2 inhibits it (Murdoch, et al. 1993, 





roles in regulating corpus luteum (CL) function. Thus, whereas PGE2 exhibits luteotropic effects, 
PGF2α is the strongest known luteolytic insult (Niswender, et al. 2000, Pharriss and Wyngarden 
1969, Weems, et al. 2006). Being mainly produced in the uterus, for transport of PGF2α to the 
ovary a transit through a counter-current mechanism from the utero-ovarian vein to the ovarian 
artery has been proposed (Ginther 1974). In addition, administration of PGF2α can also shorten 
postpartum intervals and is routinely used in reproductive cycle synchronization in livestock (Islam 
2011, Weems, et al. 2006). Contrasting with these effects, in species like the dog, cattle and sheep, 
PGE2 stimulates luteal production of progesterone (P4), which is essential for the maintenance of 
pregnancy (Kim, et al. 2001, Kowalewski, et al. 2013, Niswender, et al. 2000, Stouffer and 
Hennebold 2015, Weems, et al. 1998). Thus, based on the available literature and empirical 
applications, it appears clear that the balance between PGE2- and PGF2α-driven effects in the CL is 
crucial for regulation of the female reproductive cycle. 
 
1.2. Morpho-functional aspects of luteal formation and function  
Progesterone is the dominant steroid of diestrus. It is crucial for the regulation of female 
reproduction. For its synthesis, cholesterol is converted by cytochrome P450 side-chain cleavage 
(P450scc; located at the inner mitochondrial membrane) into pregnenolone, which is then converted 
by 3β-hydroxysteroid dehydrogenase (3βHSD; found in the endoplasmic reticulum) into P4 (Stocco 
2001). The rate-limiting step in the steroidogenic pathway is the transfer of cholesterol from the 
outer to the inner mitochondrial membrane in order to provide P450scc with the substrate. This step 
is mediated by the steroidogenic acute regulatory protein [(STAR) (Stocco 2001)]. The main targets 
of P4 during diestrus are the ovary itself (CL), the hypothalamus-hypophysis axis and the uterus 
(reviewed in Niswender, et al. 2000). In the hypothalamus-hypophysis axis, P4 blocks 
gonadotropin-releasing hormone (GnRH) signaling, by decreasing hypothalamic release of this 
hormone and hypophysial sensitivity to it, thereby decreasing the production of luteinizing hormone 
(LH) by the adenohypophysis (reviewed in Niswender, et al. 2000). In this way, P4 regulates, at 
least in part, the length of the reproductive cycle. In the uterus, this hormone is implicated in the 
modulation of endometrial protein expression, induction of stromal differentiation, stimulation of 
glandular secretion and inhibition of myometrial contractions (reviewed in Niswender, et al. 2000). 
For these reasons, a constant supply of P4 is indispensable for the successful outcome of pregnancy. 
Initially, in all mammals, the source of P4 is the CL which can be later replaced in some species by 
other sources such as the placenta, e.g., in humans or sheep (Stouffer and Hennebold 2015). In other 
species, like dogs, the constant provision of luteal P4 is essential for the success of pregnancy 
(Concannon, et al. 1989).  
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The CL is a highly complex tissue, composed of steroidogenic cells, endothelial cells, pericytes, 
fibroblasts and immune cells (Fraser and Wulff 2003). CL formation is a singular event in adult 
mammals, exhibiting intense proliferative, differentiative and tissue remodeling processes (Stouffer 
and Hennebold 2015). Following the preovulatory LH surge and ovulation, the CL is formed from 
the remaining follicular cells. Nevertheless, the process of luteinization commences prior to 
follicular rupture, involving both mural granulosa and theca interna cells (Niswender, et al. 2000). 
Then, following ovulation, the follicular antrum collapses and the basal membrane is disrupted, 
with theca cells being dislocated into the follicular cavity and differentiating into luteal cells 
(Stouffer and Hennebold 2015). In most domestic mammals, two populations of luteal cells can be 
discerned: large luteal cells, derived predominantly from the granulosa layer, and small luteal cells, 
derived from the theca interna layer (Corner 1919). However, this situation does not apply to the 
domestic dog, in which only one type of luteal cell can be observed morphologically and 
functionally (Hoffmann, et al. 2004b, Kowalewski, et al. 2015).  
As with other endocrine glands, the CL requires a large blood supply. For this reason, the CL 
contains a dense vascular network that allows, directly or through the interstitial space, access of all 
luteal cells to blood vessels (Martelli, et al. 2009). Therefore, at the time of ovulation, the 
breakdown of the basal membrane allows blood vessels to spread into the follicular cavity, 
accompanied by extravasation of blood (Fraser and Wulff 2003, Stouffer and Hennebold 2015). 
This is continued in the form of intensive angiogenesis (Fraser and Wulff 2003). Several factors are 
involved in this process, including vascular endothelial growth factor (VEGF) family members and 
angiopoietin (ANGPT) system members (Fraser and Wulff 2003, Stouffer and Hennebold 2015). 
Among the most potent angiogenic factors stimulating endothelial cell proliferation, migration and 
tube formation, is VEGF (Ferrara and Davis-Smyth 1997).  Acting through its receptors -1 and -2 
(VEGFR1 and VEGFR2) it enhances vascular permeability, allowing vascular sprouting (Ferrara 
and Davis-Smyth 1997, Fraser and Wulff 2003, Kamat, et al. 1995). VEGFA expression is 
regulated by LH, indicating the modulatory capacity of hormones over luteal vascularization (Fraser 
and Wulff 2003, Hazzard and Stouffer 2000). In addition, other non-mitogenic vascular factors, like 
angiopoietins (ANGPTs), are also important for vascular development. Both ANGPT1 and -2, as 
well as their tyrosine kinase receptors Tie1 and -2, are present in the CL, localized in different 
cellular compartments, including luteal, endothelial and immune cells (Fraser and Wulff 2003, 
Gram, et al. 2018, Stouffer and Hennebold 2015). ANGPT1 acts as a stabilizer of blood vessels 
through the recruitment of pericytes, while ANGPT2 loosens them (Brindle, et al. 2006, Hanahan 
1997, Hazzard and Stouffer 2000). In the absence of other angiogenic factors, ANGPT2 destabilizes 
blood vessels, leading to their degeneration (Felcht, et al. 2012, Hazzard and Stouffer 2000, 





disaggregation fosters the proliferation of endothelial cells (Felcht, et al. 2012, Hanahan 1997, 
Yancopoulos, et al. 2000). Accordingly, the ratio ANGPT1:ANGPT2, as well as the interaction 
between the VEGF- and ANGPT systems, appear to be essential in the development and 
maintenance of luteal vascularization. Complementing the functions of VEGFs and ANGPTs in 
regulating luteal function, endothelins (ETs) are involved in the regulation of vascular contractility 
(Schneider, et al. 2007, Yanagisawa, et al. 1988, Yanagisawa and Masaki 1989). Their roles in 
regulating the CL relate to processes of vascularization, steroidogenesis and arrest of luteal activity 
(Apa, et al. 1998, Meidan and Levy 2007). 
 
The population of immune cells in the CL varies greatly throughout its life span (Hoffmann, et al. 
2004a, Nowaczyk, et al. 2017, Pate and Keyes 2001, Stouffer and Hennebold 2015, Walusimbi and 
Pate 2013). In fact, both ovulation and luteolysis are considered inflammatory processes (Duffy, et 
al. 2019, Espey, et al. 2004, Niswender, et al. 2000, Pate and Keyes 2001, Stouffer and Hennebold 
2015, Walusimbi and Pate 2013). During luteolysis a recruitment of immune cells to the CL and 
increased production of cytokines and other immune modulators is observed in several species, e.g., 
primates, dogs, ruminants, pigs and rodents (Nowaczyk, et al. 2017, Pate and Keyes 2001, Stouffer 
and Hennebold 2015, Walusimbi and Pate 2013). The immune system is involved in phagocytosis 
of degenerated cells, stimulation of luteal PGF2α secretion and inhibition of steroidogenic activity 
(reviewed in Niswender, et al. 2000). On the other hand, it is also involved in luteal development 
and function. Thus, e.g., in mice, depletion of macrophages disrupts the angiogenic process and, 
thereby, luteal integrity (Care, et al. 2013, Turner, et al. 2011). In exerting their actions, immune 
cells interact with and modulate the function of different luteal cell populations. However, the full 
extent of roles of the immune system in regulating the CL, as well as immune cell recruitment and 
interaction with other luteal cells, is still not well understood. 
 
Despite the important role of the CL in female reproduction, knowledge regarding its regulation and 
function is still incomplete. The complexity and temporary nature of this organ present several 
obstacles to its research. In fact, the CL is composed of several cellular populations that may 
present stage-dependent (i.e., luteal development, maintenance or regression) variations in their 
presence and/or function. Finally, the presence of several luteotropic factors, like gonadotropins 
(FSH and LH), PRL, PGs and P4, and their different species-specific effects, also limits the 




1.3. Species-specific features of canine reproduction 
1.3.1. Overview of the canine reproductive cycle and main endocrinological features 
When compared with other mammals, the canine reproductive cycle exhibits several unique 
characteristics regarding its duration and main regulatory mechanisms. The main endocrine events 
in the canine reproductive cycle are shown in Fig. 2. 
Being monoestric and generally a non-seasonal breeder, the bitch has a relatively long reproductive 
cycle when compared with other domestic mammals (Concannon 2011, Kowalewski 2018). One of 
the main contributors to this cycle length is the presence of a long and obligatory anestrus period 
(Concannon 2011, Kowalewski 2018).  
A characteristic feature of the canine reproductive cycle is the strong preovulatory luteinization, 
which already starts during proestrus, and the consequent shift in follicular steroid production 
towards P4 synthesis (Kowalewski 2018, Kowalewski, et al. 2015). Indeed, the degree of 
preovulatory luteinization appears to be stronger in the dog than in other domestic mammals 
(Bischoff 1845, Concannon 2009, 2011, Feldman and Nelson 2004, Kowalewski 2017, 
Kowalewski, et al. 2015). The LH surge occurs at the end of proestrus. Spontaneous ovulation is 
observed approximately 24-72h after the LH surge, triggered by the decrease in the E2:P4 ratio, and 
takes place at circulating P4 levels of at least 5 ng/ml (Concannon, et al. 1989, Feldman and Nelson 
2004, Kowalewski 2018). This marks the ovarian beginning of diestrus (also called metestrus in 
some publications), characterized by the presence of luteal activity and P4 dominance (Concannon, 
et al. 1989, Feldman and Nelson 2004, Hoffmann, et al. 1992, Kowalewski 2018). However, 
clinical signs of the transition from estrus to diestrus are observed later, with the termination of 
estrus behavior and a change in vaginal epithelial cytology appearance from superficial cells to 
intermediate or parabasal cells (Concannon 2011, Feldman and Nelson 2004, Kowalewski 2017). 
Taking into account the delay between endocrinological and clinical signs, for research purposes, 
the time of ovulation is considered the beginning of diestrus (Kowalewski 2017).  
 
In the dog, the CL exhibits prolonged activity through the whole of diestrus, being the sole source 
of P4 in both pregnant and non-pregnant cycles as the placenta does not produce steroids 
(Hoffmann, et al. 1994, Nishiyama, et al. 1999). With the progression of diestrus, the highest levels 
of P4 are reached between days 15 to 30 post ovulation (p.o.), averaging 30 to 35 ng/ml, but with 
some animals exhibiting levels as high as 90 ng/ml (Concannon 2011, Concannon, et al. 1989, 
Hoffmann, et al. 1992). Afterwards, P4 levels start to decrease, accompanying the passive slow 
regression of the CL (Concannon, et al. 1989, Feldman and Nelson 2004, Kowalewski 2014). In 
pregnant animals, late activity of the CL (while undergoing regression) is suddenly interrupted 





(Concannon, et al. 1989, Feldman and Nelson 2004, Kowalewski 2014). The prepartum luteolytic 
cascade is induced by increased PGF2α produced mainly by the fetal placenta, terminating diestrus 
and allowing parturition to occur (Gram, et al. 2013, Gram, et al. 2014, Hoffmann, et al. 1994, 
Kowalewski, et al. 2010, Luz, et al. 2006).  
In contrast to what is observed in livestock, the absence of pregnancy in the dog is not decisive for 
luteal maintenance and function. Interestingly, the constitutive expression of FP/PTGFR in the 
canine CL makes it sensitive to exogenously applied PGF2α, despite the high dosage and repetitive 
treatment required for termination of luteal function (Kowalewski, et al. 2008b, Romagnoli, et al. 
1991). However, the intra-CL levels of PGF2α are low and the existence of a uterine luteolysin 
(PGF2α) in the absence of pregnancy has been ruled out, as hysterectomy does not affect ovarian 
function (Hoffmann, et al. 1992, Kowalewski, et al. 2009a, Kowalewski, et al. 2008b).  
During most of diestrus, P4 circulating levels in pseudopregnant bitches are similar to those in 
pregnant animals (Steinetz, et al. 1989). As in the presence of pregnancy, concentrations of P4 in 
non-pregnant dogs start to decrease slowly after day 35 p.o., associated with regression of the CL 
(Concannon, et al. 1989, Feldman and Nelson 2004, Kowalewski 2014). The passive luteal 
regression/degeneration is associated with P4 levels fading out slowly until basal levels below 
1ng/ml in peripheral plasma are reached, signaling the cycle entering the stage of anestrus 
(Concannon 2011, Concannon, et al. 1989, Kowalewski 2014).  
Thus, by lacking an active luteolytic mechanism, non-pregnant bitches exhibit a physiological 
pseudopregnancy with a long-lasting luteal activity, frequently longer than in pregnant animals 
(Feldman and Nelson 2004, Hoffmann, et al. 1992, Kowalewski, et al. 2013). 
 
Regarding E2 in diestrus, following the postovulatory drop, circulating levels increase again around 
day 10 after ovulation and appear to follow the secretion patterns of P4 [(Fig. 2) (Concannon 2011, 
Concannon, et al. 1989)]. However, they never reach their preovulatory concentrations (highest 
concentrations 45-120 pg/ml), remaining between 15-40 pg/ml (Concannon 2009, Feldman and 
Nelson 2004, Kowalewski 2018). Also, contrasting with other domestic animals, no pregnancy 
and/or parturition-associated increase of E2 is observed, the latter pointing towards the luteal source 




Figure 2. Representation of the main endocrinological features of the canine reproductive cycle 
(adapted from Kowalewski 2018). Day 0 marks the day of ovulation. “Relative gonadotropic independence” 
and “Hypophysial support required” relate to the need for gonadotropins for the maintenance and function 
of the CL throughout diestrus.  
 
1.3.2. Luteal development 
As the only source of P4, expectedly, the canine CL depends on several factors and mechanisms to 
maintain its normal function. As in other species, it relies on a dense vasculature for its 
development and function. During the canine early luteal phase, the expression of VEGF-system 
members is increased in vascular and steroidogenic cells in both pregnant and non-pregnant animals 
(Gram, et al. 2015a, Mariani, et al. 2006). This expression pattern appears to reflect the high 
angiogenic activity required for luteal development, while suggesting the presence of a cross-talk 
between steroidogenic and vascular cell populations. In parallel with the increased vascular and 
metabolic activity of the CL, the upregulation of glucose transporter 1 (GLUT1/SLC2A1) occurs, 
further indicating the need for an increased blood flow to fulfil CL metabolic needs (Kowalewski 
2017, Papa, et al. 2014). This can also be seen in the expression patterns of other vasoactive factors, 
such as ETs (Gram, et al. 2015b). In fact, the increased expression of the endothelin converting 
enzyme 1 (ECE1), a regulator of ET availability, is accompanied by upregulation of ET2 and of the 
vasodilator endothelin receptor B (ETB) in the early luteal phase (Gram, et al. 2015b). Also, 
members of the ANGPT-system, which are regulators of vascular stability, were detected in the CL 
of pregnant bitches, with the expression of ANGPT1 and Tie1 decreasing during prepartum 





both ANGPTs and Tie1 were also identified in macrophages, suggesting the involvement of the 
immune system in angiogenic and vascular processes in the dog (Gram, et al. 2018). In these 
regards, CL development is characterized by an increased invasion by CD4, CD8 and MHCII 
positive cells, mainly macrophages and lymphocytes, accompanied by an increased expression of 
immune factors like endoglin (END), tumor necrosis factor α (TNFα) and its receptors (Hoffmann, 
et al. 2004a, Nowaczyk, et al. 2017). After decreasing during mid-diestrus, a new infiltration of 
MHCII and CD8 positive cells can be observed in the regressing CL, while an increased expression 
of MHCII, TNF receptor 2 (TNFR2), IL1β, CCL3 and CCL13 is found during prepartum luteolysis 
(Hoffmann, et al. 2004a, Nowaczyk, et al. 2017, Zatta, et al. 2017). In addition, the expression of 
different interleukins, such as IL8, IL10 and IL12, and other cytokines, like transforming growth 
factor β (TGFβ), were previously identified by qualitative PCR in the canine CL (Engel, et al. 
2005). Nevertheless, the roles of these immunoactive cells and factors in the canine CL are still not 
fully elucidated. 
 
1.3.3. Luteotropic support – Gonadotropins and Progesterone 
Hypophysial support is important for the function of the canine CL, as both LH and PRL exhibit 
luteotropic effects in the dog (Concannon 1980, Okkens, et al. 1990, Okkens, et al. 1986, Onclin, et 
al. 2000). In particular, PRL is an indispensable factor for the maintenance of CL function after 
approximately day 25, as the disruption of PRL signaling with bromocriptine (an agonist of 
dopamine receptors) decreases luteal production of P4 and induces premature CL degeneration 
(Okkens, et al. 1990, Onclin and Verstegen 1997, Onclin, et al. 2000). Also, these effects can be 
reversed with exogenous PRL administration, but not with LH (Okkens, et al. 1990). In the early 
stages, however, hypophysial support appears not to be required in the dog, as hypophysectomy had 
low to no effects on CL function in the first 2 – 4 weeks after ovulation (Okkens, et al. 1986). 
Consequently, the canine CL appears to be at least in part independent of gonadotropins in its early 
stages (Fig. 2).  
Interestingly, the increasing availability of PRL through diestrus does not prevent CL regression, 
suggesting that this hypophysial hormone has a supportive role rather than being an active 
stimulator of CL function (Concannon, et al. 2009, Okkens, et al. 1990, Onclin and Verstegen 1997, 
Onclin, et al. 2000). However, the programmed regression of the CL, in combination with its 
independence from gonadotropins during development, suggests that the CL lifespan is inherently 
regulated through some local auto/paracrine mechanisms. In these regards, the expression of the 
nuclear P4 receptor (PGR) and estrogen receptors (ERα/ESR1 and ERβ/ESR2) in the canine CL 
throughout diestrus suggests a possible regulatory role of these hormones (Hoffmann, et al. 2004b). 
In fact, P4 appears to have luteotropic effects in the dog as the disruption of PGR signaling with 
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antigestagens (i.e., mifepristone or aglepristone) induces preterm luteolysis and/or abortion (Baan, 
et al. 2005, Hoffmann, et al. 2004b, Kowalewski, et al. 2009a, Kowalewski, et al. 2010). 
Auto/paracrine effects of estrogens in the canine CL were also previously proposed, but, despite 
some efforts being made, their role in luteal function remains elusive (Hoffmann, et al. 2004b, Papa 
and Hoffmann 2011). 
 
1.3.4. Luteotropic role of prostaglandins in the dog including study with Previcox 
The expression of COX2 and PTGES is observed in the luteal tissue through diestrus (Kowalewski, 
et al. 2009a, Kowalewski, et al. 2008a, Kowalewski, et al. 2006). Their expression is higher in the 
early gonadotropin-independent CL than during luteal regression (Kowalewski, et al. 2009a, 
Kowalewski, et al. 2008a, Kowalewski, et al. 2006). In addition, the canine CL is also sensitive to 
PGE2 throughout its life span, expressing both PTGER2 and PTGER4 (Kowalewski, et al. 2009a, 
Kowalewski, et al. 2008a). This prompted the idea that PGs, in particular PGE2, could perform 
luteotropic actions in this species. Indeed, such actions were observed in early canine luteal cells 
stimulated in vitro with PGE2, which exhibited increased expression of STAR and higher P4 output 
(Kowalewski, et al. 2013).  
 
The decisive clues regarding the luteotropic effects of PGs in the dog came from our in vivo study, 
in which withdrawal of luteal PGs was achieved by the administration of firocoxib (Previcox®, 
Merial), a COX2-specific inhibitor, to bitches during the first half of diestrus (Janowski, et al. 2014, 
Kowalewski, et al. 2015). With this treatment, the expression of PTGES and the intra-CL levels of 
PGE2 were decreased during the period of CL independence from gonadotropins, demonstrating the 
connection between COX2 and the PTGES-dependent synthesis of PGE2 in the canine CL 
(Kowalewski, et al. 2015). This also showed the effectiveness of treatment in decreasing intra-CL 
PGs. In addition, treated animals displayed lower circulating levels of P4, accompanied by 
decreased expression of STAR and 3βHSD (Janowski, et al. 2014, Kowalewski, et al. 2015). 
Noteably, the effects on P4 levels were rather variable and, despite the decreased activity, CL 
function was not terminated by COX2-inhibition (Janowski, et al. 2014). Besides these effects on 
steroidogenic properties, other, indirect, effects of PGE2 in the canine CL were described. 
Accordingly, in vitro, PGE2 modulated the expression of different vascular factors in canine luteal 
cells, like ET2, ETB, ANGPT1 and ANGPT2 (Gram, et al. 2015b, Gram, et al. 2018). Also, 
modulatory effects of PGs regarding hormonal sensitivity of the CL were observed. In vivo, PRLR 
was downregulated following PGs withdrawal and PGE2 could upregulate this receptor in canine 





treatment with Previcox, suggesting that PGs withdrawal also affected the transcriptional activity of 
luteal cells (Janowski, et al. 2014).  
Cumulatively, the observations so far indicate the presence of direct (on steroidogenesis) and 
indirect (on vascularization, hormonal sensitivity and transcriptional activity) effects of PGE2, and 
possibly other PGs, in the regulation of canine luteal physiology.  
 
Cumulatively, the dog exhibits a unique reproductive cycle when compared with other domestic 
mammals, with the CL providing a central role in the regulation of canine reproduction. Thus, a 
good understanding of CL physiology is fundamental for the study of canine reproduction.  
As discussed above, the regulation of CL activity can be divided into two main parts: an early 
developing CL independent of gonadotropic support, and a mature/regressing CL that requires 
primarily the support of PRL for maintenance of its function. During the early stage, PGs, mainly 
PGE2, play an important role in the regulation of CL function. This independent phase also appears 
to present the dog as an interesting model to study CL regulation without the presence of 
gonadotropins as major regulatory factors. Nevertheless, a better understanding of the luteotropic 













Based on the previously observed effects of in vivo suppression of PGs on canine CL function 
(Janowski, et al. 2014, Kowalewski, et al. 2015), as well as the in vitro effects of PGE2 in 
steroidogenesis (Kowalewski, et al. 2013), the general hypothesis pursued in this PhD work is that: 
(1) Prostaglandins, mainly PGE2, exert biological effects on the corpus luteum of the 
domestic dog, indicating an important luteotropic role during early diestrus. 
 
Adding to the direct effects of PGE2 in the steroidogenic activity of the canine CL, indirect effects 
could also be observed including impairment of the CL sensitivity to PRL (Kowalewski, et al. 
2015) and modulatory effects on the expression of vascular factors (Gram, et al. 2015b, Gram, et al. 
2018). Finally, PGE2 has been described in both pro- and anti-inflammatory mechanisms in several 
tissues (Kalinski 2012, Nakanishi and Rosenberg 2013). For these reasons, we further hypothesize 
that: 
(2) PGE2 might perform broader modulatory roles in the early canine CL besides the 
cAMP-dependent regulation of steroidogenesis, in particular regarding CL 
vascularization and immune system 
 
Finally, the withdrawal of PGs by application of Previcox affected CL function but did not induce 
termination of CL activity (Janowski, et al. 2014, Kowalewski, et al. 2015). Thus, we also 
hypothesized that: 




Luteal samples from the previous in vivo study (Janowski, et al. 2014, Kowalewski, et al. 2015) 
were available and used in the current PhD work. In this study, bitches from different breeds and 
ages were monitored for the onset of spontaneous ovulation and then allotted to either control or 
treated groups. From the day of ovulation, bitches were treated daily with 10 mg/kg of firocoxib 
(Previcox®, Merial) administered orally (treated groups) or receiving a placebo (control groups). 
Treatments were applied for 5, 10, 20 or 30 days p.o. On the last day of treatment, the ovaries were 
collected by ovariohysterectomy (OHE) and the corpora lutea were dissected and processed for 
histological or molecular analyses (n=3-5 animals/group). In addition, samples from the day of 
ovulation (day 0) were also available (n=5). Thus, using these samples, the following aims were 
defined to validate the described hypotheses: 
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Aim 1: Investigation of the spatio-temporal expression and localization of selected vasoactive, 
immunoactive and steroidogenic factors in the early canine CL during the normal cycle and 
in Previcox-treated animals. 
This aim was accomplished by evaluating differences in the expression of several target genes in 
response to treatment in samples from days 0, 5, 10, 20 and 30 p.o. Selected genes included 
vascular factors (members of the VEGF-, ANGPT- and ET-systems) and immunoactive factors 
(CD4, CD8, MHCII, IL1β, IL6, IL8, IL10, IL12a, END, TGFβ and members of the TNFα family). 
Additionally, possible modulatory functions of PGs on the following functional groups of genes 
were assessed: estrogen receptors (ERα/ESR1 and ERβ/ESR2), regulators of STAR expression 
(cJun, SF1, YY1, GATA4 and GATA6) and of the cell cycle (CCNA2). The effects on gene 
expression were evaluated by applying semi-quantitative real time (TaqMan) qPCR (RT-qPCR), 
and were further validated at the protein level by immunohistochemistry (IHC). This allowed 
localization of these targets within the CL of treated and control animals. In addition, by having 
available control samples from different stages of luteal development, i.e., early gonadotropin-
independent CL (days 5 and 10), transition to dependence on hypophysial support (day 20) and the 
mature CL dependent on PRL (day 30), time-dependent changes in the expression of all factors 
during the first half of diestrus were investigated.  
 
Aim 2: Characterization of transcriptional changes observed in the canine CL during early 
diestrus and in response to the withdrawal of PGs  
In order to achieve this aim, deep sequencing analysis of mRNA (RNA-Seq) from canine corpora 
lutea obtained from the Previcox study was performed with Next Generation Sequencing (NGS; 
deep RNA sequencing, RNA-Seq). The effects of treatment were evaluated by comparing samples 
from control and treated dogs at each analyzed time-point. In addition, time-dependent effects in 
luteal transcriptional patterns were evaluated by comparing control samples from early developing 
CL (days 5 and 10) with samples from the mature and fully developed CL (days 20 and 30). 
Identified differentially-expressed genes (DEGs) were grouped by their biological functions. 
Specific signaling pathways and functional networks were analyzed allowing prediction of those 
pathways that were more affected by treatment, together with their specific upstream regulators. 
Broad and multidirectional effects of treatment were observed, being also stage-dependent. Further, 
genes affected by treatment that might be involved in the response to the withdrawal of PGs were 
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4.2. Manuscript 2: Global transcriptomic analysis of the canine corpus 
luteum (CL) during the first half of diestrus and changes induced by in 
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5.1. Effects of Previcox treatment in the early canine CL 
(Tavares Pereira, et al. 2019a; Tavares Pereira, et al. 2019b)  
 
The independence of the canine CL on hypophysial support during its development is indeed one of 
the most interesting species-specific peculiarities in this species (Okkens, et al. 1990, Okkens, et al. 
1986). This unique regulatory characteristic suggests that other factors may be involved in 
regulating development and function of early canine CL. Among them, PGs appear to be major 
players, in particular PGE2 acting through its cAMP-mediating receptors, PTGER2 and PTGER4 
(Kowalewski 2014). Until recently, our knowledge regarding PGs effects in the canine CL was 
limited to the cAMP-dependent activation of steroidogenesis by PGE2, and its modulatory effects 
observed in vitro on the expression of PRLR, PTGER2, ETB, ET2, ANGPT1 and ANGPT2 (Gram, 
et al. 2015b, Gram, et al. 2018, Kowalewski, et al. 2013, Kowalewski, et al. 2015). Some of these 
effects were confirmed in our in vivo studies, further indicating the effects of PGs in regulating CL 
sensitivity to PRL (Kowalewski, et al. 2015). Thus, based on these previously published results, the 
present PhD thesis aimed to further investigate effects of Previcox-mediated withdrawal of PGs on 
the physiology of the canine CL.  
 
Several effects have been attributed to PGs in different organs and systems, including those related 
to the modulation of vascular function and immune response (Breyer, et al. 2001, Hata and Breyer 
2004). Accordingly, the investigations presented in Manuscript 1 (Tavares Pereira, et al. 2019a) 
focused on changes in the luteal expression of a selected range of factors from both these groups.  
Regarding angiogenic and/or vasoactive factors, among the most interesting findings were the 
suppressive effects of treatment on all studied factors from the ANGPT-system. These contrasted 
with the absence of effects on VEGFA expression. As previously mentioned, interactions between 
the ANGPT system and VEGF are indispensable for normal angiogenesis, in which the loosening 
of blood vessels by ANGPT2 is required for the VEGF-induced angiogenic sprouting (Felcht, et al. 
2012, Hanahan 1997, Yancopoulos, et al. 2000). In this way, adding to the effects PGE2 exerts on 
ANGPT family members in vitro (Gram, et al. 2018), here, the involvement of PGs in the 
regulation of luteal vascular development and maintenance has been confirmed by applying an in 
vivo approach. Following this avenue, regarding ETs, in the presented PhD thesis we also observed 
increased availability of ET1 in response to PGs-withdrawal on day 20. This finding suggests a 
modulatory capability of PGs upon the luteal blood supply mediated through the ET system.  
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Contrasting with CL formation and luteolysis, a lower presence of immune factors is observed in 
the mature CL (Hoffmann, et al. 2004a, Nowaczyk, et al. 2017, Zatta, et al. 2017). In this context, it 
was interesting to observe that the inhibition of COX2 in the CL resulted in enhanced expression of 
CD4 at day 30 and potentiated the expression of pro-inflammatory interleukins -1β, -6 and -12 at 
day 20 of the luteal phase. Therefore, the study presented herein for the first time implies the 
immunomodulatory, presumably immunosuppressive, roles of PGs in the CL, clearly indicating 
translational value of our findings to the understanding of CL function in other mammals as well.  
 
The vaso- and immuno-modulatory roles of PGs in the canine CL described in Manuscript 1 
pointed towards new, as yet undescribed, luteal roles of these eicosanoids. This prompted us to 
obtain a deeper insight into underlying regulatory mechanisms by applying the transcriptomic 
approach. This was achieved by the deep RNA sequencing method, as presented in Manuscript 2 
(Tavares Pereira, et al. 2019b). Differential expression analyses (pairwise comparisons) were 
performed by comparing treated with control samples at each time-point (days 5, 10, 20 and 30 
p.o.). Several target candidate genes were selected for validation of data and their expression was 
assessed by RT-qPCR. Functionally, these genes involved factors relating to eicosanoid synthesis, 
immune system, growth factors, vascular regulators, nuclear receptors and steroid-related factors.  
Interestingly, samples distribution/homogeneity (observed in a PCA plot) appeared to rely more on 
the developmental stage of the CL than treatment, as two main clusters of samples could be 
observed: samples from the early developing CL (days 5 and 10 p.o.) formed one cluster, whereas 
the other was formed by samples from the developed CL (days 20 and 30). Nevertheless, significant 
effects of treatment could still be observed. After performing pairwise comparisons, differentially- 
expressed genes (DEGs) were filtered with the following criteria of P-value < 0.01 and False 
Discovery Rate (FDR, adjusted P-value) < 0.1. Day 20 was the most affected time-point, exhibiting 
1741 DEGs, followed by day 30 with 552 DEGs. Interestingly, small effects of treatment were 
observed in the early CL stages, where 72 DEG were found on day 5 and 2 DEG on day 10 p.o. 
Interestingly, no gene was found to be concomitantly affected at all time-points. Cumulatively, 
these observations account for the most important discoveries from our investigations, as they 
deeply elaborate the time and development related genomic effects of Previcox treatment in the 
canine CL. These results also corroborate findings described in Manuscript 1 where most of the 
significant effects were observed on days 20 or 30 after ovulation.  
 
Below, the main effects evoked by Previcox on the luteal transcriptome at major developmental 





5.1.1. Gonadotropin-independent stage of the CL (days 5 and 10) 
In previous studies, Previcox treatment affected PGE2 synthesis and the steroidogenic function of 
the canine CL during the early gonadotropin-independent stage (Janowski, et al. 2014, Kowalewski, 
et al. 2015). Interestingly, these diminishing effects seemed not to be strongly observed in the 
present NGS analysis at this stage. It appears, however, plausible that the high variation among 
treated samples observed at this time, and the differences in sensitivity between qPCR and NGS 
methods, together with the stringent criteria of P-Value and FDR applied in RNA-Seq analysis, 
might have led to low numbers of DEGs found in transcriptomic analysis for the early (days 5 and 
10) CL. On the other hand, these weak transcriptomic effects of treatment also suggest a resilience 
of the gonadotropin-independent CL to PGs-withdrawal, implying a strong intrinsic regulation of 
CL function at this stage.  
Nevertheless, among the interesting findings observed at day 5 was the increased expression of 
thrombospondin 1 (THBS1) and downregulation of fibroblast growth factor 2 (FGF2) in response 
to treatment. THBS1 is an anti-angiogenic and pro-apoptotic factor that, in the bovine CL, is 
associated to luteolytic events (Niswender, et al. 2000, Schams and Berisha 2004). THBS1 can also 
block the expression and function of the pro-angiogenic FGF2 in bovine luteal cells in vitro 
(Farberov and Meidan 2014, 2016, Gospodarowicz , et al. 1986, Maroni and Davis 2011). Thereby, 
the results presented in the PhD thesis at the transcriptomic level further reinforce the presence of 
negative effects of PGs withdrawal on luteal angiogenesis.  
 
5.1.2. Transition towards gonadotropin-dependence of the CL (day 20) 
Highly contrasting with the effects observed in earlier gonadotropin-independent stages of the CL, 
as mentioned above, the highest number of DEGs identified after functional COX2 inhibition was 
found at day 20 of treatment. This stage represents the transition between the independence from 
gonadotropins and the required support of PRL for CL activity. One of the most important findings 
at this stage was the predicted activation of canonical pathways linked to immune activity after 
treatment. This observation was further supported by the increased expression observed herein of 
several pro-inflammatory factors, such as ICAM1, NODAL, FAS, FASLG and NFκB1 (Tavares 
Pereira, et al. 2019b), as well as the increased expression of IL1β, IL6 and IL12a (Tavares Pereira, 
et al. 2019a). Thus, an increased genomic immune reaction was observed after withdrawal of PGs 
in the canine CL on day 20 of the luteal stage.  
Also interesting was the observed decreased expression of the vascular stabilizer ANGPT1 and of 
the pro-angiogenic FGF2, accompanied by the increased expression of the anti-angiogenic THBS1 
and ET1. The possible interaction between THBS1 and FGF2 was also implied above for day 5 of 
Previcox treatment. The increase of ET1 expression was previously associated with luteolysis in 
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several species, e.g., ruminants, rats and rabbits (Boiti, et al. 2007, Hinckley and Milvae 2001, Ko, 
et al. 2012, Milvae 2000), and it was upregulated after the induction of luteolysis in mid-pregnant 
bitches treated with aglepristone (Gram, et al. 2015b). Following this, Previcox treatment also 
appeared to affect the stabilization of luteal vascularization at this stage.  
Cumulatively, immuno- and vaso-modulatory effects of treatment were observed at this stage (day 
20 p.o.). Further effects described previously related, e.g., to downregulation of STAR, 3βHSD and 
PRLR after treatment (Janowski, et al. 2014, Kowalewski, et al. 2015). With this, the transition 
between gonadotropin-independent and -dependent stages appears to be the most sensitive stage for 
inhibition of COX2-mediated PG synthesis in the first half of diestrus.  
 
Following the observed decreased expression of STAR and lower P4 circulating levels after COX2-
inhibition (Janowski, et al. 2014, Kowalewski, et al. 2015), we also investigated possible PG-
dependent effects on the expression of factors regulating STAR transcription. Accordingly, cJUN is 
a well-known and one of the strongest regulators of STAR transcription (Stocco 2001) and its 
decreased expression was observed, concomitantly with decreased STAR levels, in pregnant dogs 
during prepartum luteolysis (Zatta, et al. 2017). For this reason, it was perplexing to observe the 
upregulation of cJUN after Previcox treatment. Similarly, CCNA2, a cell cycle regulator, was 
upregulated at day 20, when the transcriptional activity of luteal cells appeared to be decreased 
(Janowski, et al. 2014). The expression patterns observed herein of cJUN and CCNA2 were 
interpreted as a part of the compensatory response to treatment. This, as well as the presence of 
other, still unknown, compensatory mechanisms might explain why, despite luteal function being 
affected, it was not terminated after treatment (Janowski, et al. 2014, Kowalewski, et al. 2015). The 
compensatory effect could also explain the high variation in gene expression levels observed after 
treatment. Nevertheless, as mentioned elsewhere, it should also be noted that individual variations, 
the small number of animals per group, or even the pharmacokinetics of Previcox affecting its 
ovarian availability, could account for these observed variations. 
  
As discussed before, the modulation of CL function is frequently attributed to the balance between 
PGE2 and PGF2α. For this reason, it was interesting to observe an increased expression of 
TBXAS1 and PTGDS in response to COX2-inhibition in animals from day 20 p.o. To the best of 
our knowledge, this is the first time the presence of these synthases has been described in the canine 
CL. Although possible roles of these eicosanoids in the CL are still unknown, one of the PGD2 
targets might be the nuclear receptor PPARγ (Fitzpatrick and Wynalda 1983, Herlong and Scott 
2006, Kikawa, et al. 1984, Komar 2005), which was also observed to be upregulated at day 20 in 




modulate a plethora of cellular mechanisms including pro-inflammatory response, by acting on 
NFκB or steroidogenesis, by indirectly increasing STAR expression through cJUN-dependent 
activation of its transcriptional activity (Delerive, et al. 1999, Kim, et al. 2007, Komar 2005, 
Kowalewski, et al. 2009b). Considering these broad effects of PPARγ, it is possible that the 
increased expression of PPARg might be related to the increased expression of cJUN and/or 
increased immune signalling observed at this stage, which is a topic worth further investigations. 
 
We were also interested in investigating PGs-mediated regulation of CL sensitivity to steroids. 
However, no effects of treatments with Previcox were observed on the luteal expression of 
ERa/ESR1 and ERb/ESR2 at any time-point studied (Tavares Pereira, et al. 2019a). Together with 
the previously reported lack of effects of treatment on PGR expression (Kowalewski et al. 2015), 
these results suggest that the withdrawal of PGs has no effect on CL sensitivity to steroids. 
Nevertheless, an interesting finding was the upregulation of SULT1E1 in treated animals on day 20. 
SULT1E1 disrupts (by sulfoconjugation) the capacity of estrogens to bind to their receptors and in 
this way modulates availability of estrogens in target tissues (Song 2001). This finding suggests that 
PGs may still influence luteal estrogenic signaling by regulating the local provision of estrogens 
through SULT1E1 activity, rather than by modulating the nuclear ERs.  
 
5.1.3. Gonadotropin-dependent stage of the CL (day 30) 
Day 30 represents the mid-diestrus CL that depends on gonadotropin support for its function and 
exhibits high P4 production. In the transcriptomics analysis, canonical pathways related to 
vascularization were predicted to be inactivated by treatment at this stage. This was in concordance 
with the observed decreased expression of ANGPT2, Tie1 and Tie2. Additionally, the predicted 
inhibition of immune pathways at this stage was accompanied by the increased presence of factors 
like TNF, PPARγ, TGFβ and NFκBIA among the predicted upstream regulators for the observed 
changes in the transcriptome profile. This highly contrasted with the upregulation of several pro-
inflammatory factors on day 20. Concomitantly, pathways linked to lipid metabolic process and 
steroidogenesis were also predicted to be inhibited in animals that received Previcox at day 30. 
Considering the dependence of the CL on PRL at this stage, it is possible that the observed effects 
could be indirectly induced through downregulation of the PRLR, as previously suggested 
(Kowalewski, et al. 2015). Furthermore, by presenting the diverging results obtained between days 
20 and 30, mainly regarding immunomodulatory effects, the results obtained from this PhD thesis 





In summary:  
With the results presented herein, the initial hypotheses underlying the present PhD thesis could be 
successfully confirmed. Thus, indeed, PGs exert multidirectional biological effects on the CL of the 
domestic dog, going beyond their functions in cAMP-dependent regulation of STAR. There are 
strong compensatory effects present in the CL upon withdrawal of PGs.  
 
In particular we were able to show:  
1) Broader and potentially novel roles of PGs in the regulation of the canine CL. 
2) Effects of COX2-inhibition in the canine CL being clearly stage-dependent:  
a. Only weak effects were observed in the early independent CL stage, with treatment 
apparently having negative effects in the vascular development already as early in the luteal 
phase as at day 5 after ovulation.  
b. The transition towards gonadotropin dependence (represented by day 20 in the present study) 
appeared to be the most sensitive stage to treatment. COX2 inhibition remarkably stimulated 
pro-inflammatory responses in the CL, besides affecting different vascular factors. Covertly, 
these effects suggested an (immuno)protective role of PGs in the CL at this stage. 
c. Multidirectional effects of PGs withdrawal were observed in the transition to gonadotropin 
dependence (day 30). Effects of treatment on immune signaling at day 30 highly contrasted 
with the ones observed on day 20. Treatment also had a negative effect in steroidogenic 
activity and vascularization at this stage. 
3) Changes in the expression of members of the ANGPT-system, ET1, THBS1 and FGF2 indicate 
an indirect role of PGs in the regulation of angiogenic processes and vascular stabilization in the 
canine CL.  
4) Additional factors and mechanisms possibly involved in the regulation of CL function were 
identified. Some hypotheses that might be worth pursuing involve the possible SULT1E1-
dependent regulation of local supply of estrogens in the canine CL in response to PGs, the 
THBS1/FGF2 interaction during the vascularization process, and the PPARγ-dependent effects 
of PGD2 in steroidogenesis and immune system activity.  
 
5.2. Time-related changes in canine CL activity during the first half of diestrus 
(Tavares Pereira, et al. 2019a; Tavares Pereira, et al. 2019b)  
 
During development of the present PhD work, the availability of samples from control animals 
provided a great opportunity to evaluate time-dependent changes in gene expression during the 




factors possibly involved in the maturation and maintenance of the CL, with the expression of 
several genes being evaluated for the first time in the non-pregnant canine CL. Those include, i.a., 
the ANGPT and ET systems, eNOS and iNOS, THBS1, FGF1 and -2, ICAM1, TBXAS1 and 
PTGDS, as well as selected transcription factors involved in steroidogenesis, like cJUN, YY1, SF1, 
GATA4 and GATA6.  
Considering the homogeneity of samples observed in the transcriptome analysis, estimated by their 
clustering in the PCA plot, the following contrast was created to study time-dependent effects: 
“days 20+30 control vs. days 5+10 control”. From this contrast, a total of 3484 DEGs were found. 
Interestingly, mirroring the expected biological activity of the CL, together with the progression of 
its development and maturation, canonical pathways related to the immune system and cellular 
proliferation were predicted to be deactivated. This is in accordance with the previously described 
invasion of immune cells and upregulation of pro-inflammatory factors during CL development 
(Hoffmann, et al. 2004a, Nowaczyk, et al. 2017). At the gene expression level, elevated amounts of 
pro-inflammatory factors like IL10, ICAM1, CD4, TGFβ1 and NFκBIA were initially found, 
decreasing with the maturation of the CL, i.e., towards days 20 and 30 p.o. In addition, the TNF 
system was among the predicted upstream regulators. In fact, the expression of TNFα and TNFR1 
was higher on day 5 p.o., decreasing with CL maturation. Similarly, the expression of FAS and 
FASLG was higher in the developing CL, consistent with their similar expression patterns observed 
previously during CL formation in the cow (Duncan, et al. 2012). It has been concluded the 
FAS/FASLG might be involved in immune mechanisms and morphological remodeling of the 
developing CL of the dog. Furthermore, following the predicted deactivation of cellular 
proliferation, the expression of CCNA2 decreased between days 5 and 20 after ovulation.  
In a different direction, pathways linked to cholesterol synthesis and steroidogenesis were predicted 
to be activated during CL maturation. This is in accordance with published data because the mature 
CL exhibits increased expression of STAR, accompanied by higher output of P4 (Concannon 2011, 
Concannon, et al. 1989, Hoffmann, et al. 1992, Kowalewski and Hoffmann 2008). Also, 
corresponding with the increasing levels of STAR, the expression of SF1 increased towards 
maturation of the CL.  
Another interesting finding from this project was the higher expression of THBS1 on day 5 p.o., 
compared with days 20 and 30. Considering the anti-angiogenic properties of THBS1, the increased 
expression of this factor during CL development was surprising. The ongoing remodeling processes 
or limitation of vascular overgrowth suggested previously by others (Petrik, et al. 2002) might be 
explanatory. In addition, the increased expression of TBXAS and PTGDS in early CL stages also 
suggests a role of TBXA1 and PGD2 in the development of the canine CL. 
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Similar to previous descriptions (Gram, et al. 2015b), the expression of ET2 decreased during the 
formation of the canine CL in the present work. However, contrasting with the absence of time 
effects observed in pregnant bitches (Gram, et al. 2015b, Gram, et al. 2018), the expression of 
ECE1, ANGPT2, Tie1 and Tie2 increased between the developing and mature CL stages in the 
present project. It should be, however, mentioned that the time-points and intervals studied 
previously in samples from pregnant animals (p.o. days 8-12, 18-25, 35-40, and prepartum 
luteolysis) diverge from the ones studied here (days 0, 5, 10, 20 and 30), which might explain the 
differences observed for gene expression in both studies. Regardless, the results obtained herein 
suggest the increased luteal availability of vasoactive factors towards maturation of the CL. 
Exhibiting a similar tendency, ETB expression was the lowest on the day of ovulation, increasing 
thereafter, concomitantly with elevated transcript levels of the inducible nitric oxide synthase 
(iNOS) and of endothelial nitric oxide synthase (eNOS). Apparently, thus, as in other species, in the 
dog also the vasodilatory effects of ETB are accomplished by activation of the nitric oxide pathway 
(Schneider, et al. 2007, Yanagisawa, et al. 1988).  
Finally, in accordance with a previous report (Papa and Hoffmann 2011), time-dependent changes 
in the expression of estrogen receptors were observed in the present work. Interestingly, the higher 
availability of ESR1 and ESR2 in the matured CL was followed by similar expression patterns of 
HSD17B7 observed by NGS analysis. The latter, i.e., HSD17B7, is involved in the estrone (E1) to 
estradiol (E2) conversion (Nokelainen, et al. 1998, Stocco, et al. 2007), suggesting its involvement 
in the local supply of E2 in the canine CL.  
 
In summary:  
1) The time-dependent changes in the transcriptomic profile relate predominantly to cellular 
proliferation, activation of the immune system and steroidogenic function, and support the 
current views about canine luteal physiology (Kowalewski 2014).  
2) New factors possibly involved in underlying biological and molecular mechanisms have been 
indicated. Accordingly, the expression of several factors involved in CL vascularization, immune 
system activity, availability of estrogens and regulation of STAR promoter activity were for the 
first time investigated in the canine CL.  
3) Based on the described expression of PTGDS and TBXAS1, the capacity of the canine CL to 
synthesize eicosanoids other than PGE2 was described for the first time in the present PhD work. 
Regardless, the role of these eicosanoids in CL physiology is still unknown.  
4) Despite the role of estrogens in the CL of the dog still being obscure, the expression patterns of 
HSD17B7 suggest its involvement in the local availability of these steroids. 
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6. Further studies and outlook   
6.1. Expression profiles of PTGDS, TBXAS1 and factors involved in estrogen 
signaling in the canine CL during diestrus and potential modulatory roles of 
PGE2 
6.1.1. Rationale  
In the present PhD work, the expression of several factors in the canine CL, e.g., TBXAS1, 
PTGDS, SULT1E1 and HSD17B7, was investigated for the first time. Furthermore, the CL 
responses to Previcox implied new regulatory mechanisms. One of the most interesting was the 
possible regulation of local provision of E2 in the CL by SULT1E1 and HSD17B7. However, their 
expression was investigated only in the first 30 days of pseudopregnancy (Tavares Pereira, et al. 
2019b). Thus, we aimed to further explore the presence of these factors in the CL throughout 
diestrus in both pregnant and non-pregnant animals. Additionally, the expression of ESR1, ESR2, 
and of the steroids sulfatase (STS), involved in counter-acting the inhibitory effects of SULT1E1 on 
E2 (Cole, et al. 2010, Purohit, et al. 1998, Rizner 2016), was investigated.  
Moreover, as mentioned elsewhere, the expression of TBXAS1 and PTGDS suggested modulatory 
roles of TXA2 and PGD2 in the canine CL. The possible interaction between PGD2 and PPARγ, as 
well as the upregulation of these factors in response to treatment with Previcox, led us to investigate 
the expression of TBXAS1, PTGDS and PPARγ throughout diestrus. Considering the effects PGs-
withdrawal had in vivo on the expression of several of these factors, we also investigated possible 
PGE2-mediated effects on the expression of these factors in vitro in early canine luteal cells.  
 
6.1.2. Materials and methods 
Luteal tissue samples from pregnant animals used in the present study were derived from our 
previous works (Gram, et al. 2015b, Kowalewski, et al. 2009a). Additionally, samples from non-
pregnant bitches where kindly provided by Prof. Dr. Paula Papa (University of São Paulo, São 
Paulo, Brazil). Briefly, bitches from mixed breeds were monitored for the onset of spontaneous 
estrus by vaginal cytology and P4 assay. The day when P4 levels exceeded 5ng/ml was considered 
the day of ovulation. Non-pregnant samples (n = 5 animals/group) were then collected after 10, 20, 
30, 40, 50 and 60 days. For pregnant samples, animals were mated 2 days after ovulation (day of 
mating was considered day 0 of pregnancy). Samples were then collected at the pre-implantation 
(days 8-12, n = 6), post-implantation (days 18-25, n = 5) and mid-gestation (days 35-40, n = 5) 
stages, and during pre-partum luteolysis (n = 4). The pre-implantation stage was confirmed by 
observing embryos in uterine flushes. To ensure the occurrence of pre-partum luteolysis, circulating 
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P4 levels were measured every 6h starting with day 58 of pregnancy until a continuous decrease in 
3 consecutive measurements was observed. Corpora lutea were collected through OHE, dissected 
from surrounding tissues, placed in RNAlater for 24h at +4ºC and then stored at -80ºC until use.  
Corpora lutea for luteal cell cultures were obtained from clinically healthy bitches (n = 3) in the 
early diestrus stage (days 14-21) that underwent routine OHE in the Department of Small Animals 
Reproduction, Vetsuisse Faculty, University of Zürich. Primary luteal cells were isolated and 
cultured as previously described (Kowalewski, et al. 2013) in 6-well plates with culture medium 
(DMEM/F12, pH 7.2-7.4, with 10% heat-inactivated FBS, 100 U/ml penicillin and 100 mg/ml 
streptomycin, and 1% Insulin-Transferrin-Selenium). When 70-80% confluence was reached, the 
culture medium was replaced by serum-free medium (stimulation medium); cells were stimulated 
either with 1.0 mM N6,2-dibutyryladenosine-3,5-cyclic monophosphate (dbcAMP; positive 
control) or with 20 µM PGE2 for 6 h, which is the time period needed for maximal activation of 
STAR (Kowalewski, et al. 2013). Cells were collected with TRIzol and kept at -80ºC until RNA 
isolation. The expression of STAR was investigated in cAMP- and PGE2-treated cells for positive 
control (not shown ((Kowalewski, et al. 2013)). 
The isolation of total RNA with the TRIzol reagent was performed following the manufacturer’s 
protocol. The concentration and purity of RNA were measured with NanoDrop 2000c 
spectrophotometer. DNAse treatment for removal of possible DNA contamination and reverse 
transcription (RT) were done according to the previously published protocols (Kowalewski, et al. 
2011, Kowalewski, et al. 2006). Finally, the total amount of cDNA was amplified using the 
TaqMan PreAmp Master Mix Kit and RT-qPCR and was performed as previously described 
(Tavares Pereira, et al. 2019a). All reactions were run in duplicate and negative controls were 
performed by replacing cDNA with autoclaved water and minus-RT control. Quantification of gene 
expression was performed by the ΔΔCt method (Kowalewski, et al. 2011, Kowalewski, et al. 2006), 
using the expression of three reference genes for data normalization (PTK2, KDM4A and EIF4H). 
Due to uneven distribution of RT-qPCR results, logarithmic transformation was performed and data 
are presented as geometric means (Xg) ± geometric standard deviation (SD). Evaluation of time-
dependent effects was done by using the Kruskal-Wallis test (non-parametric ANOVA) followed by 
Dunn’s test, while evaluation of cell culture results was performed with One-way parametric 
ANOVA followed by Dunnett’s multiple comparison test, using controls as reference.  
 
6.1.3. Main findings and physiological implications 
All investigated target genes were found expressed in the studied samples.  
Regarding eicosanoids synthases, no changes in the expression of TBXAS1 and PTGDS were 
observed during pregnancy (P>0.05, Fig. 3A and C). This strongly contrasted with their time-
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dependent expression during non-pregnant diestrus (P<0.0001 for TBXAS1 and P<0.0009 for 
PTGDS, Fig. 3B and D). Thus, the expression of TBXAS1 was higher on day 40 than at any earlier 
time-point (P<0.05), and decreased subsequently towards day 60 (P<0.05, Fig. 3B). Also, PTGDS 
expression was significantly lower on day 30 when compared with the later stages of 
pseudopregnancy (P<0.05, Fig. 3D). In our previous study, the expression of PTGDS and TBXAS1 
was highest on day 5 p.o., when compared with days 10, 20 and 30 (Tavares Pereira, et al. 2019b). 
Following this, the absence of day 5 in the present study may explain the lack of effects during 
luteal development. Nevertheless, the increased expression of these factors in the second half of 
diestrus, mainly at days 40 and 50, is quite interesting, as during this stage the expression of COX2 
and of PTGES is decreased (Kowalewski, et al. 2008a, Kowalewski, et al. 2006). Adding this to the 
upregulation of these factors after the inhibition of COX2 on day 20 (Tavares Pereira, et al. 2019b), 
it appears that the expression of TBXAS1 and PTGDS might be increased in response to the 
decreased availability of COX2. Furthermore, similar to previous descriptions in pregnant bitches 
(Kowalewski, et al. 2011), no significant changes in the expression of PPARγ were observed in 
both pregnant and non-pregnant samples (P>0.05, Fig. 3E and F).  
Regarding sensitivity to estrogens, stage-dependent effects in the expression of ESR1 (ERa) in 
pregnant animals were noted (P<0.0001), being lower (P<0.001) during pre-implantation than at 
mid-gestation (Fig. 4A). However, no significant effects in the expression of this factor were 
observed in pseudopregnant animals (P>0.05, Fig. 4B). Also, ESR2 (ERb) remained stably 
expressed in both conditions (P>0.05, Fig. 4C and D). Considering the frequently opposing effects 
exerted by these receptors, as observed, e.g., in the mouse uterus where ERα promoted cellular 
proliferation while ERβ inhibited it (Weihua, et al. 2000), we further evaluated the expression ratio 
between ESR1 and ESR2. Interestingly, despite the high variation, this ratio decreased from early- 
(pre-implantation) to mid-gestation (P< 0.01), but increased significantly at prepartum luteolysis 
(P< 0.05, Fig. 4E). The receptor ratio was also higher in the slowly regressing CL on days 40 and 
50 compared with the developing CL at day 10 (P<0.05 and P<0.01 respectively, Fig. 4F). 
Although effects of estrogens in the canine CL still need to be investigated, the possible 
involvement of these receptors in the regulation of cellular proliferation could explain the variations 
in the ESR1:ESR2 ratio observed herein. It needs, however, to be mentioned that the extent to 
which the data obtained at the transcript level would transfer to the ERa and ERb protein levels 
remains to be investigated.  
The expression of SULT1E1 increased from pre-implantation to mid-gestation (P<0.01), 
i.e., from approximately days 10-12 to 30-45 of pregnancy. It decreased thereafter, during 
prepartum luteolysis (P<0.01, Fig. 5A). A similar expression pattern was observed in non-pregnant 
dogs, in which SULT1E1 levels increased significantly between days 20 and 50 (P<0.05, Fig. 5B). 
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However, no decrease was observed during late regression of the CL, at day 60. Instead, SULT1E1 
remained highly expressed at day 60 compared with day 30 (P<0.05, Fig. 5B). Due to its mentioned 
opposite activity to SULT1E1, the expression of STS was also investigated in the present study. In 
the CL of pregnant animals, STS appeared to present an opposite expression pattern to SULT1E1: it 
was abundantly expressed from pre-implantation to mid-gestation, but its representation was 
significantly lower in luteolytic CL compared with the pre-implantation stage (P<0.05, Fig. 5C). 
However, despite being continuously detectable in the CL of non-pregnant animals, STS did not 
differ significantly throughout diestrus in non-pregnant animals (P>0.05, Fig. 5D).  
Also, the basic availability of HSD17B7 varied throughout diestrus (P<0.0001 in pregnant 
and P<0.0003 in non-pregnant animals, Fig. 5E and F). Its expression was higher during pre-
implantation (P<0.01) and post-implantation (P<0.001) than in later stages of pregnancy (Fig. 5E). 
The first drop in its expression was noticed at mid-gestation (P<0.05), and it remained low 
thereafter, until prepartum luteolysis. In non-pregnant bitches, following the initial gradual increase 
towards day 40 after ovulation, the expression of HSD17B7 was suppressed (p<0.05) at day 50 
(Fig. 5F).  
As for the luteal cells, we found modulatory effects of PGE2 on ESR2 (ERb) and PPARg (Fig. 6A 
and B). Whereas ESR2 was positively affected (P<0.05), the expression of PPARg was significantly 
suppressed (P<0.01). The expression of other factors was not affected by the treatment with PGE2 
(P>0.05). In Manuscript 1 presented in this thesis (Tavares Pereira, et al. 2019a), the responsiveness 
of the CL to estrogens appeared to be unaffected by the withdrawal of PGs in vivo, contrasting with 
the results obtained here in vitro. These diverging effects might be caused by the high individual 
variation observed in the in vivo study. With regard to the diminishing effects of PGE2 on PPARg 
expression, this negative response further suggests that the previously observed increase of PPARγ 
in COX2-inhibited samples (Tavares Pereira, et al. 2019b) might be due to the decrease of PGE2 
within the CL (Kowalewski, et al. 2015). Considering that PPARγ was previously shown to have 
indirect effects on the expression of STAR (Kowalewski, et al. 2009b), these observations further 
support the role of PPARγ in a compensatory mechanism to the decreased PGE2-dependent 
steroidogenic activity of the canine CL.  
It should be mentioned that while PPARγ mRNA levels remained unaffected, lower protein levels 
were observed during prepartum luteolysis in a previous study (Kowalewski, et al. 2011). For this 
reason, evaluation of protein levels appears required to confirm the effects presented herein . In 
fact, the investigation of protein levels and localization of some of the factors analyzed in this work 
is planned and will allow a deeper and more complete evaluation of their role in the canine CL. 
Nevertheless, the presented (unpublished) results suggest the involvement of PGD2, TBXA1, 
PPARγ and estrogens in the regulation of CL physiology in the dog.  







Figure 3. Relative gene expression of TBXAS1, PTGDS and PPARγ in the canine CL during 
pregnancy (A, C, E) and in non-pregnant diestrus (B, D, F) as determined by RT-qPCR (Xg ± SD). 
The sample with the lowest expression of each target gene was used as calibrator. Kruskal-Wallis (non-
parametric ANOVA) was performed to evaluate time-dependent changes in gene expression during diestrus 
and revealed: (A) P = 0.9229, (B) P < 0.0001, (C) P = 0.7734, (D) P = 0.0009, (E) P = 0.1103, (F) P = 
0.2608. When P < 0.05, Dunn’s multiple comparison was performed and results are presented in the graphics 
(dotted lines).  
 




Figure 4. Relative gene expression of ESR1 (encoding for ERa), ESR2 (encoding for ERb), and ratio 
between ESR1 and ESR2 expression in the canine CL during pregnancy (A, C, E) and non-pregnant 
diestrus (B, D, F) as determined by RT-qPCR (Xg ± SD). The sample with the lowest expression of each 
target gene was used as calibrator. Kruskal-Wallis (non-parametric ANOVA) was performed to evaluate 
time-dependent changes in gene expression during diestrus and revealed: (A) P < 0.0001, (B) P = 0.2395, (C) 
P = 0.8643, (D) P = 0.4541, (E) P= 0.002, (F) P= 0.0056. When P < 0.05, Dunn’s multiple comparison was 
performed and results are presented in the graphics (dotted lines).  





Figure 5. Relative gene expression of SULT1E1, STS and HSD17B7 in the canine CL during 
pregnancy (A, C, E) and non-pregnant diestrus (B, D, F) as determined by RT-qPCR (Xg ± SD). The 
sample with the lowest expression of each target gene was used as calibrator. Kruskal-Wallis (non-
parametric ANOVA) was performed to evaluate time-dependent changes in gene expression during diestrus 
and revealed: (A) P = 0.0012, (B) P= 0.0002, (C) P = 0.0139, (D) P = 0.1958, (E) P < 0.0001, (F) P = 0.0003. 
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Figure 6. Relative gene expression of ESR2 (encoding for ERb) and PPARγ in early primary canine luteal cells in 
the absence or presence of PGE2 as determined by RT-qPCR (Xg ± SD). Student’s unpaired t-test was performed 
and revealed: (A) P = 0.0004 and (B) P = 0.0072.  
 
6.2. Outlook 
Despite the central role of the CL in canine reproduction, the regulatory mechanisms involved in its 
function and maintenance are still far from being fully understood. The stage-dependent differences 
in gene expression and response to treatment described in the present PhD work further highlight 
the complex mechanisms present in the regulation of canine CL function. In these regards, cell 
cultures, as applied in our still ongoing additional studies, are a useful tool to investigate effects in 
individual cellular populations, but lack the flexibility to explore cellular interactions. Thus, the 
development of a different model for the CL, where this cellular interaction could be assessed, 
appears to be needed.  
Regardless, we were able to further explore the regulation of the canine CL in the present PhD 
thesis, uncovering new aspects of PGs activity. Nevertheless, as indicated above, the regulation of 
the canine CL still needs to be better explored, and the clinically available tools to modulate the 
canine reproductive cycle are limited. Thus, further understanding of canine reproduction, with a 
special focus on CL function, is still required for the development of new strategies to modulate the 
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